Effect of treatment by GNRH agonist on infertility in PCOD patients
Phase 3
- Conditions
- Patients with hyper androgenic polycystic ovarian disease.Female infertility associated with anovulation
- Registration Number
- IRCT20140818018842N15
- Lead Sponsor
- Deputy of Research and Technology, Tehran University of Medical Sciences.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 74
Inclusion Criteria
Oligoovulation or anovulation.
Clinical and/or biochemical signs of hyperandrogenism.
Polycystic ovaries.
Exclusion Criteria
Patients with hyperanderogenism caused by hormonal drugs or other medications.
Patients who have known sever organ dysfunction or mental illness.
Pregnant women or being in Post- miscarriage period
breastfeeding
being in the 6 week postpartum period.
Patients had congenital adrenal hyperplasia or were suspected of having Cushing s syndrome or an androgen – screening neoplasm.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Endometrium thickness. Timepoint: Before starting treatment and embryo transfer. Method of measurement: Trans vaginal ultrasonography.;The number of positive chemical pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: Laboratory test (BHCG over than 40 IU).;The number of successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Trans vaginal ultrasonography.
- Secondary Outcome Measures
Name Time Method ive birth rate. Timepoint: At 28th week of pregnancy. Method of measurement: Trans abdominal ultrasonography.